Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35% (NASDAQ:ETON)

seekingalpha.com · 2026-08-14

Eton Pharmaceuticals (ETON) Q2 2026 earnings call recap: record revenue, raised 2026 guidance to $145M+ and 35%+ EBITDA, plus ASN-001 updates—read now.

Read the full story at seekingalpha.com →